Grant: Engage Grants Program
Université du Québec à Montréal
$25,000.00
Synthesis of carbohydrate lectin inhibitors as anti-inflammatory drug targets
EF 2012-13
Résumé
Bacterial drug resistance is a prevalent and central worldwide bottleneck. Infections with resistant organisms
lead to adverse clinical outcomes, increased mortality, and are costly to healthcare systems. Several infectious
diseases are initiated by the binding of pathogenic lectins to host cells glycocans. The molecular understanding
of these adhesion phenomena is crucial and presents promising new alternatives compared to traditional
antibiotic therapies. Glycans mimetics could be used to inhibit the initial recognition events leading to adhesion
and colonization of host tissues by pathogens. The bladder and urothelial lining are widely covered by cell
surface glycoproteins bearing the required carbohydrate ligands responsible for the adhesion phenomena.
However, when these interactions are measured on a per saccharide basis, they are generally too weak for the
design of beneficial inhibition therapies. Uropathogenic Escherichia coli (UPEC) strains are the major causal
agents of urinary tract infections. During infection, UPEC adhere to mannosylated glycoreceptors on the
urothelium via the FimH adhesin located at the tip of type 1 pili. Synthetic FimH anti-adhesives such as
modified alpha-D-mannopyranosides are therefore ideal ""hit"" candidates for the chemical interception of this
important step in pathogenesis. Roy at UQAM, an expert in the field of glycan mimetics, and Vertex
Pharmaceuticals will join their efforts to improve the design of potent inhibitors against fimbriated type 1 E.
coli. This will constitute the first collaborative initiative between the two parties. Vertex will be responsible for
testing the novel glycomimetics, prepared at UQAM, on their own cell and bacterial strains. They will also
offer expertise in computer modeling that will complement crystallographic data obtained by the UQAM team.
The company's expertise in drug design will permit a faster guiding in drug development together with
knowledge in pharmacokinetic and pharmacodynamic properties. The collaboration will greatly accelerate the
development of a new drug candidate. The outcome of this project will be the advancement of the science and
discovery of potential drugs.
Programme
Engage Grants Program
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
434720-2012
Name nom
Roy, René
Department département
Chimie
Organization id
57
Institution établissement
Université du Québec à Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2012
Competition year année de concours
2012
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1552
Committee name en
Quebec Internal Decision Committee
Committee name fr
Comité de décision interne pour le Québec
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
3702
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Carbohydrates
Research subject fr
Glucides
Partie
1
Nb partie
1
Application title
Synthesis of carbohydrate lectin inhibitors as anti-inflammatory drug targets
Keyword
NSERC
Application summary
Bacterial drug resistance is a prevalent and central worldwide bottleneck. Infections with resistant organisms
lead to adverse clinical outcomes, increased mortality, and are costly to healthcare systems. Several infectious
diseases are initiated by the binding of pathogenic lectins to host cells glycocans. The molecular understanding
of these adhesion phenomena is crucial and presents promising new alternatives compared to traditional
antibiotic therapies. Glycans mimetics could be used to inhibit the initial recognition events leading to adhesion
and colonization of host tissues by pathogens. The bladder and urothelial lining are widely covered by cell
surface glycoproteins bearing the required carbohydrate ligands responsible for the adhesion phenomena.
However, when these interactions are measured on a per saccharide basis, they are generally too weak for the
design of beneficial inhibition therapies. Uropathogenic Escherichia coli (UPEC) strains are the major causal
agents of urinary tract infections. During infection, UPEC adhere to mannosylated glycoreceptors on the
urothelium via the FimH adhesin located at the tip of type 1 pili. Synthetic FimH anti-adhesives such as
modified alpha-D-mannopyranosides are therefore ideal ""hit"" candidates for the chemical interception of this
important step in pathogenesis. Roy at UQAM, an expert in the field of glycan mimetics, and Vertex
Pharmaceuticals will join their efforts to improve the design of potent inhibitors against fimbriated type 1 E.
coli. This will constitute the first collaborative initiative between the two parties. Vertex will be responsible for
testing the novel glycomimetics, prepared at UQAM, on their own cell and bacterial strains. They will also
offer expertise in computer modeling that will complement crystallographic data obtained by the UQAM team.
The company's expertise in drug design will permit a faster guiding in drug development together with
knowledge in pharmacokinetic and pharmacodynamic properties. The collaboration will greatly accelerate the
development of a new drug candidate. The outcome of this project will be the advancement of the science and
discovery of potential drugs.